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William F. Fearon, MDnABSTRACTOBJECTIVES This study compared the diagnostic performance with adenosine-derived fractional ﬂow reserve
(FFR) #0.8 of contrast-based FFR (cFFR), resting distal pressure (Pd)/aortic pressure (Pa), and the instantaneous wave-
free ratio (iFR).
BACKGROUND FFR objectively identiﬁes lesions that beneﬁt from medical therapy versus revascularization. However,
FFR requires maximal vasodilation, usually achieved with adenosine. Radiographic contrast injection causes submaximal
coronary hyperemia. Therefore, intracoronary contrast could provide an easy and inexpensive tool for predicting FFR.
METHODS We recruited patients undergoing routine FFR assessment and made paired, repeated measurements of all
physiology metrics (Pd/Pa, iFR, cFFR, and FFR). Contrast medium and dose were per local practice, as was the dose
of intracoronary adenosine. Operators were encouraged to perform both intracoronary and intravenous adenosine
assessments and a ﬁnal drift check to assess wire calibration. A central core lab analyzed blinded pressure tracings in a
standardized fashion.
RESULTS A total of 763 subjects were enrolled from 12 international centers. Contrast volume was 8  2 ml per
measurement, and 8 different contrast media were used. Repeated measurements of each metric showed a bias <0.005,
but a lower SD (less variability) for cFFR than resting indexes. Although Pd/Pa and iFR demonstrated equivalent per-
formance against FFR#0.8 (78.5% vs. 79.9% accuracy; p ¼ 0.78; area under the receiver-operating characteristic curve:
0.875 vs. 0.881; p ¼ 0.35), cFFR improved both metrics (85.8% accuracy and 0.930 area; p < 0.001 for each) with an
optimal binary threshold of 0.83. A hybrid decision-making strategy using cFFR required adenosine less often than when
based on either Pd/Pa or iFR.
CONCLUSIONS cFFR provides diagnostic performance superior to that of Pd/Pa or iFR for predicting FFR. For
clinical scenarios or health care systems in which adenosine is contraindicated or prohibitively expensive, cFFR
offers a universal technique to simplify invasive coronary physiological assessments. Yet FFR remains the reference
standard for diagnostic certainty as even cFFR reached only w85% agreement. (J Am Coll Cardiol Intv 2016;9:757–67)
© 2016 by the American College of Cardiology Foundation.
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758D iagnostic accuracy can be thoughtof as a pyramid (Figure 1). At thebase of the pyramid, useless tests
provide an accuracy of 50%, no better than
an unbiased coin ﬂip; at the pinnacle, a gold
standard reaches 100% accuracy; and in be-
tween these extremes, we ﬁnd the vast ma-
jority of our daily tools in medicine. Our
general task is to rank-order new and exist-
ing tests so that we can make rational choices
to reach a diagnosis and thereby improve pa-
tient outcomes by altering treatment (1).SEE PAGE 768As a speciﬁc example, the diagnosis of
signiﬁcant coronary artery disease can pose a clinical
challenge, especially in patients with ambiguous
symptoms, intermediate or multiple angiographic
stenoses, and absent, equivocal, or conﬂicting non-
invasive testing. To assist with these dilemmas,
fractional ﬂow reserve (FFR) was uniquely validated
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Two potential strategies modify this requirement,
but with a reduction in diagnostic accuracy. First,
resting physiology as used by Andreas Grüntzig et al.
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FIGURE 1 Contrast Hyperemia Within the Pyramid of
Diagnostic Accuracy
Accuracy of any test must exist between 50% (equivalent to a
coin ﬂip) and 100% (the gold standard). By itself, the diagnostic
angiogram has an accuracy of w65% (18). Adding resting
physiology increases the accuracy to w80% (5,10). However,
hyperemia uniquely increases the accuracy, ﬁrst to 85% using
contrast injection and then to at least 95% using potent vaso-
dilators like adenosine (2).
FIGURE 2 Example of Protocol
Complete example from the study that demonstrates essentially no gradient at rest (high
Pd/Pa and iFR) with a clearly positive result by cFFR then conﬁrmed by both intracoronary
and intravenous adenosine FFR. No signiﬁcant drift was observed, and each metric was
measured twice (#1 and #2). Aortic pressure (Pa) in red, distal coronary (Pd) in blue,
and their ratio Pd/Pa in black. cFFR ¼ contrast-based fractional ﬂow reserve; IC ¼
intracoronary; iFFR ¼ instantaneous wave-free ratio; Pd/Pa ¼ resting ratio of distal
coronary pressure to aortic pressure.
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759Therefore, we compared the diagnostic perfor-
mance and repeatability of cFFR and resting physi-
ology (both resting ratio of distal coronary pressure
to aortic pressure [Pd/Pa] and instantaneous wave-
free ratio [iFR]) with FFR, ordering all metrics
within the pyramid of diagnostic accuracy. Given
the continuum between hyperemic physiological
severity and clinical outcomes (8), quantifying the
parallel continuum of vasodilator stress potency
clariﬁes the trade off when using submaximal
hyperemia to guide revascularization.
METHODS
We performed an investigator-initiated, prospective
diagnostic accuracy study that enrolled a multicenter,
international cohort of patients undergoing routine
FFR assessment for standard indications. Subsequent
care proceeded as per routine from the clinical FFR
measurement without further study-related follow-
up. Each subject gave informed consent as approved
by the local institutional review board of that
participating center. Recruitment took place between
June 2014 and April 2015.
We excluded subjects with previous coronary
bypass surgery, known severe cardiomyopathy (left
ventricular ejection fraction <30%) or left ventricularhypertrophy (septal wall thickness >13 mm), contra-
indication to adenosine, or renal insufﬁciency such
that an additional 12 to 20 ml of contrast would, in the
opinion of the operator, pose an unwarranted risk. In
cases of multivessel disease, only the ﬁrst lesion
studied using FFR was included. Culprit lesions for
an acute infarction were excluded, but nonculprit
lesions were permitted. Standard demographic, clin-
ical, and catheterization parameters were collected
for each subject.
PHYSIOLOGY PROTOCOL. Figure 2 provides a graph-
ical example of the complete physiology protocol.
An initial period of at least 1 min provided a stable
assessment of resting physiology without further
contrast injection. Next, either a manual or injector-
based IC bolus of contrast medium was given per
local practice for diagnostic angiography. To remain
pragmatic and reﬂect real-world conditions, the vol-
ume and type of IC contrast medium were not
mandated but varied among sites and even among
subjects at a single site but with a strong recommen-
dation for 6 to 10 ml. After w1 min when conditions
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760had returned to baseline, a second IC bolus of contrast
medium was injected using the same technique as
for the ﬁrst injection.
Next, after the return of baseline conditions, a
manual IC bolus of adenosine was administered.
Based on local practice and patient features, operators
selected the dose of IC adenosine, but with a strong
recommendation for 100 to 200 mg, given emerging
data regarding its dose/response curve (9). After w1
min when conditions had returned to baseline, a
second, identical bolus of IC adenosine was given.
A subsequent period of at least 1 min provided a
second assessment of resting physiology before
starting an adenosine infusion at a standard rate
of 140 mg/kg/min via either a central or wide-bore
peripheral IV line. The duration of the infusion was
w2 min, but could be prolonged or abbreviated as
necessary if a steady state had been reached or if the
patient did not tolerate it. After stopping IV adeno-
sine and waiting w2 min for conditions to return to
baseline, a second, identical IV adenosine infusion
was performed.
At the end of the procedure, an optional but rec-
ommended drift check was performed by bringing the
pressure sensor back to the guide catheter at the same
location as equalization. Operators were encouraged
to perform both IC and IV adenosine measurements
in duplicate, but all 4 were not mandatory as long as
at least one technique was repeated. In cases without
IV adenosine, the second assessment of resting
physiology occurred between the second IC contrast
and ﬁrst IC adenosine injections.
CORE LAB ANALYSIS. All pressure tracings were sent
to the Cardiovascular Research Foundation physi-
ology core lab for standardized and centralized re-
view. Operators placed bookmarks denoting each
section of the protocol, permitting objective separa-
tion of the entire pressure tracing into its anonymous
components. Thus, the core lab carried out a
post hoc analysis without knowledge of the locally
determined Pd/Pa value, IC substance (contrast
medium or adenosine), enrolling site, or subject/
lesion characteristics. Because each section of the
tracing was blinded and uncoupled from the rest,
the core lab remained unbiased by knowledge of the
other measurements for that subject.
The physiology core lab assessed tracing quality,
including inspection for aortic and coronary pressure
signal distortion or loss, aortic pressure damping, and
limiting arrhythmia. Each submitted component
tracing received a binary decision regarding adequate
quality for inclusion and an associated Pd/Pa
value (corresponding to resting Pd/Pa, cFFR, or FFRdepending on the subsection of the overall
recording). Additionally, the quality of the electro-
cardiogram was given a separate but analogous binary
assessment. Drift check recordings were rejected if of
suboptimal quality or else were given a Pd/Pa value
(ideally 1.00 without drift).
Each component tracing apart from drift checks
was analyzed separately and in automated fashion by
the software package HARVEST version 1.0.0.127
(Volcano Corporation, San Diego, California) for
iFR (under rest, contrast, or adenosine conditions).
Because HARVEST requires an electrocardiographic
signal and applies its own quality criteria to the
tracing, some additional recordings were rejected
despite being accepted by the core lab itself.
STATISTICAL METHODS AND ENDPOINTS. Analyses
were performed using R version 3.2.1 (R Foundation
for Statistical Computing, Vienna, Austria). We used
standard statistical techniques. Applicable tests were
2 tailed, and p < 0.05 was considered statistically
signiﬁcant. Additional details on the statistical anal-
ysis can be found in the Online Appendix.
The primary endpoint was accuracy against
FFR #0.8 and compared using a McNemar test
between metrics. Secondary endpoints included the
area under the receiver-operating characteristic
(ROC) curve (compared using the DeLong method),
Bland-Altman analysis, sensitivity, and speciﬁcity.
Because there could be as many as 4 FFR values for
each subject (2 IC and 2 IV), a summary FFR value was
computed by the following hierarchy: average of
2 IV values, a single IV value, the average of 2 IC
values, or a single IC value. When both test and retest
values were present, their average was used.
Following previous work (5,10), we also explored a
so-called hybrid strategy of selective adenosine
administration for intermediate values between
2 thresholds (“gray zone”) instead of no adenosine
and a single threshold as for a binary strategy.
A hybrid strategy can achieve an arbitrary accuracy
with a variable proportion of lesions within the in-
termediate range, here presented with false positives
equal to false negatives.
Existing binary thresholds of Pd/Pa <0.92 and
iFR <0.90 (5) were selected. Because no accepted
binary threshold existed for cFFR, we chose the value
that maximized accuracy but performed a sensitivity
analysis around this optimum.
Our sample size of at least 750 subjects was pro-
spectively chosen as follows. Based on simulation
work from a previous study (5), if contrast injection
provides a conservative 20% of the hyperemia
seen with adenosine, then w300 subjects would be
TABLE 1 Baseline Characteristics (N ¼ 763)
Clinical
Age, yrs 66  10
Male 547 (72)
Body mass index, kg/m2 27.3  4.7
Smoking (current or past) 363 (48)
Hypertension 545 (71)
Dyslipidemia 508 (67)
Diabetes mellitus 219 (29)
Family history of premature CAD 191 (25)
Renal insufﬁciency (GFR <60) 74 (10)
Previous MI 198 (26)
Previous PCI 114 (15)
Presentation
Stable 598 (78)
Unstable angina 84 (11)
NSTEMI 73 (10)
STEMI 8 (1)
Catheterization
Coronary vessel
Left main 25 (3)
LAD 460 (60)
LCx 138 (18)
RCA 140 (18)
Contrast medium
Iobitridol 40 (5)
Iodixanol 189 (25)
Iohexol 106 (14)
Iomeprol 227 (30)
Iopamidol 8 (1)
Iopromide 69 (9)
Ioversol 68 (9)
Ioxaglate 56 (7)
Volume of IC contrast, ml 8  2
5 17 (2)
6 or 7 324 (42)
8 or 9 210 (28)
10 211 (28)
12 1 (<1)
Dose of IC adenosine, mg* 168  46
<80 11 (2)
80 or 90 39 (7)
100–150 157 (29)
160–200 261 (48)
>200 81 (15)
Route of IV adenosine*
Central 124 (28)
Peripheral 315 (72)
Values are mean  SD or n (%). *Only 549 patients received IC adenosine and
439 received IV adenosine, whereas data in all other rows are based on N ¼ 763
total.
CAD ¼ coronary artery disease; GFR ¼ glomerular ﬁltration rate; IC ¼ intra-
coronary; IV ¼ intravenous; LAD ¼ left anterior descending coronary artery; LCx ¼
left circumﬂex coronary artery; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-
segment elevation myocardial infarction; PCI ¼ percutaneous coronary interven-
tion; RCA ¼ right coronary artery; STEMI ¼ ST-segment elevation myocardial
infarction.
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761necessary to detect the difference using a McNemar
test. Given the 20% to 25% exclusions seen in recent
physiology core labs (5,10), 300/(1  0.25) ¼ 400
subjects would be necessary. Thus, we selected at
least 750 subjects, assuming that just less than 50%
would receive both IC and IV adenosine.
ROLE OF ACADEMIC AUTHORS AND INDUSTRY.
Our investigator-initiated study was supported
ﬁnancially by St. Jude Medical. Volcano Corporation
(subsequently acquired by Royal Philips) agreed to
off-line and post hoc analysis for iFR values by the
core lab using HARVEST software. The academic
authors had full access to the data, carried out data
analysis, and wrote the manuscript independent of
industry. However, both companies reviewed the
manuscript for conﬁdential or proprietary informa-
tion but requested no changes. The trial was
prospectively registered with NCT02184117. Anony-
mous and unannotated pressure tracings for all sub-
jects have been made publically available (11).
RESULTS
A total of 763 subjects were enrolled from 12 centers.
Table 1 summarizes the demographic, clinical, and
catheterization features, all typical for a cohort
undergoing invasive assessment. The average IC
contrast volume was 8  2 ml, and 8 different contrast
media were used, reﬂecting our pragmatic and real-
world protocol.
The physiology core lab analyzed 4,946 recordings
(100%) and accepted 4,453 (90.0%), with exclusions
mainly due to damping or distortion of the aortic
pressure waveform. A total of 3,802 tracings (76.9%)
also had a sufﬁcient electrocardiogram, and HAR-
VEST produced an iFR value for 3,764 (76.1%). Addi-
tionally, the core lab analyzed 616 drift checks (80.7%
of cohort) and accepted 604 (98.1% of submitted) as
technically adequate, irrespective of the amount of
drift. Median physiological metrics for the cohort
were a Pd/Pa of 0.92 (interquartile range [IQR]: 0.88
to 0.95), an iFR 0.90 (IQR: 0.84 to 0.94), cFFR 0.85
(IQR: 0.79 to 0.91), and FFR 0.81 (IQR: 0.73 to 0.86).
Among subjects with all 3 measurements, 9.4% had a
Pd/Pa #0.8, 28.8% had either a Pd/Pa or cFFR #0.8,
and 49.2% had FFR #0.8.
TEST/RETEST REPEATABILITY. Figure 3 displays the
repeatability of physiological indexes, with a visual
impression of more scatter for resting physiology
than either contrast or adenosine hyperemia. Quan-
titative analysis supports the visual impression, with
the largest SD between repeated measurements for
iFR (0.033), intermediate for Pd/Pa (0.023), and
FIGURE 3 Repeatability
All metrics demonstrate minimal average difference when measured twice, with a bias <0.01 essentially superimposed on the thin, dashed
gray line of identity. However, hyperemic metrics of contrast FFR and FFR provide superior repeatability compared with resting metrics
of Pd/Pa and iFR, as shown visually by the raw data (black dots, many of which are superimposed) and quantiﬁed by correlation
coefﬁcients (r from Pearson, ICC from intraclass correlation) and SD of the difference. ICC ¼ intraclass correlation coefﬁcient; other
abbreviations as in Figure 2.
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762smallest and similar for cFFR and FFR (0.017 and
0.019, respectively). Comparisons of variance
conﬁrmed the trend with p < 0.001 for all pairs except
cFFR and FFR, with p ¼ 0.51 demonstrating equiva-
lence. The average difference between repeated
measurements was <0.005 for all metrics and thus
clinically insigniﬁcant.
DIAGNOSTIC PERFORMANCE. A binary threshold of
cFFR #0.83 produced an accuracy of 85.8%, superior
to both Pd/Pa (78.5%) and iFR (79.9%) (McNemar
p < 0.001 vs. both resting metrics), when compared
with FFR #0.8. The diagnostic accuracy of Pd/Pa and
iFR did not differ signiﬁcantly (p ¼ 0.78). Notably
cFFR accuracy remained >84% for thresholds 0.83 to0.85. Sensitivity remained similar among all metrics
(75.8% cFFR, 77.9% Pd/Pa, 81.1% iFR), but cFFR
improved speciﬁcity (95.3% cFFR, 79.0% Pd/Pa,
78.7% iFR). The area under the ROC curve was largest
for cFFR at 0.930 (DeLong p < 0.001 vs. both resting
metrics) and equivalent between Pd/Pa at 0.875 and
iFR at 0.881 (p ¼ 0.35) as displayed in the left panel of
Figure 4.
The right panel of Figure 4 compares hybrid stra-
tegies, visually showing the greater freedom from
adenosine when using cFFR compared with Pd/Pa
and iFR, which were similar. A speciﬁc example at
96% accuracy can be seen in Figure 4 with further
details in Table 2 for a range of potential accuracies.
As a physiological explanation for the superior
FIGURE 4 Diagnostic Performance
Using a single cutoff as shown by the ROC curves on the left, contrast FFR (red line) has the largest area under the ROC curve
(p < 0.001), whereas iFR (blue line) and Pd/Pa (black line) have equivalent areas (p ¼ 0.35). Using a hybrid strategy as shown on
the right, contrast FFR avoids adenosine most often for any desired accuracy, whereas no clinical difference exists between iFR and
Pd/Pa. For example, although a 96% accuracy can be achieved with all 3 metrics, cFFR avoids adenosine in approximately two-thirds
of the population, whereas Pd/Pa and iFR avoid adenosine in only about one-half (see the 96% row in Table 2 for values and gray
zone ranges but using 2 decimal places for thresholds). AUC ¼ area under the curve; ROC ¼ receiver-operating characteristic;
other abbreviations as in Figures 1 and 2.
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763diagnostic performance of cFFR, Figure 5 depicts the
increasingly linear relationship with decreasing
scatter versus FFR when hyperemia increases with
contrast. The equivalent diagnostic performance of
Pd/Pa and iFR can be explained through their
extremely linear relationship. Correlation betweenTABLE 2 Selective Adenosine (“Hybrid”) Performance Versus FFR #0
Rounded
Accuracy, %
Pd/Pa
Gray Zone
Need
Adenosine, % Accuracy, % Gray Zone A
100 0.83–0.99 81.5 100 0.78–1.01
99 0.86–0.97 67.4 98.8 0.80–0.97
98 0.87–0.96 59.8 98.0 0.83–0.96
97 0.88–0.96 56.5 96.9 0.84–0.95
96 0.88–0.95 50.9 95.6 0.85–0.94
95 0.86–0.94
94 0.89–0.95 46.0 94.2 0.87–0.94
93 0.87–0.93
92 0.89–0.94 38.1 92.0 0.87–0.92
90 0.90–0.94 32.0 90.0
89 0.88–0.92
88 0.90–0.93 24.7 88.1 0.88–0.91
85 0.91–0.93 18.5 84.7 0.89–0.91
83 0.89–0.90
82 0.91–0.92 10.3 82.2
cFFR ¼ contrast-based fractional ﬂow reserve; FFR ¼ fractional ﬂow reserve; iFFR ¼
aortic pressure.the 2 resting metrics was r ¼ 0.964 such that Pd/Pa
explained 93% of the iFR variation; best-ﬁt regression
of iFR ¼ 1.314  Pd/Pa  0.313 had an average
difference <0.001 with an SD of 0.031, equivalent to
the SD of 0.033 for a repeated iFR measurement
itself..8 for Balanced False Positives and Negatives
iFR cFFR
Need
denosine, % Accuracy, % Gray Zone
Need
Adenosine, % Accuracy, %
84.0 100 0.78–0.96 74.0 100
71.2 99.1 0.80–0.92 56.7 99.1
63.9 98.5 0.82–0.91 47.2 98.1
58.4 97.1 0.82–0.90 41.2 97.0
49.9 95.6 0.83–0.90 37.2 95.8
46.0 95.2 0.83–0.89 32.3 95.3
42.8 94.0 0.83–0.88 26.3 94.1
37.0 92.7 0.83–0.87 20.9 93.3
30.8 91.5
0.84–0.87 16.2 90.2
25.2 89.3 0.84–0.86 11.9 88.7
19.8 87.6 0.84–0.85 8.6 87.5
15.8 84.5
10.6 82.6
instantaneous wave-free ratio; Pd/Pa ¼ resting ratio of distal coronary pressure to
FIGURE 5 Scatterplots of Each Metric With FFR
Resting physiology (either Pd/Pa or iFR) displays a less linear and more scattered relationship with FFR than does modest hyperemia (contrast FFR), as shown visually by
the raw data (black dots) and its local regression (thick red line with dashed lines as 95% conﬁdence intervals) and quantiﬁed by correlation coefﬁcients (r from Pearson,
ICC from intraclass correlation). The thin dashed gray line represents identity. Abbreviations as in Figures 1 through 3.
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Our study clariﬁed the continuum of vasodilator
stress for IC pressure measurements as a fundamental
physiological insight linking the magnitude of
hyperemia to diagnostic accuracy (Figure 1). We
demonstrated 3 clinically important physiological
properties of the hyperemic continuum. First, hy-
peremia improves repeatability, as shown in Figure 3,
such that resting measurements carry lower precision
than those made using contrast or adenosine. Second,
contrast hyperemia outperforms resting physiology
for predicting FFR, as shown in Figure 4 and Table 2.
Third, intermediate hyperemia induced by contrast
reduces scatter and promotes a more linear relation-
ship with FFR, distinct from the wider scatter and
curvilinear relationship provided by resting physi-
ology, as shown in Figure 5.
The pyramid of diagnostic accuracy (Figure 1) pla-
ces FFR very close to its apex based on several lines of
evidence. First, FFR was validated 20 years ago in a
clinically relevant population with chest pain of un-
certain origin and a moderate stenosis in a major
coronary vessel (2). For its composite reference
standard, the study used a triad of noninvasive tests
covering electrical (bicycle electrocardiogram),
perfusion (stress single-photon emission computed
tomography), and contractile (dobutamine echocar-
diography) aspects both before and after revascular-
ization. Notably, “composite information from
sequentially performed noninvasive tests has a diag-
nostic accuracy of almost 100%,” and FFR achieved a
93% accuracy using a threshold of 0.75 (2). Second,FFR-guided revascularization improved a variety of
outcomes in 3 major randomized outcomes trials
(12–14) when added to clinical symptoms, noninva-
sive testing, and invasive angiography. Third, FFR
has been shown to be cost saving versus angiography
to guide percutaneous coronary intervention (15) and
cost-effective to select PCI instead of medical therapy
(16). These aspects of excellent repeatability (17), high
diagnostic accuracy, improved patient outcomes in
randomized trials, and proven cost-effectiveness
together form the key criteria when evaluating any
diagnostic test (1), including FFR.
Angiographic evaluation alone achieved an accu-
racy of 66% compared with FFR in a study of >1,000
lesions analyzed by quantitative coronary angiog-
raphy (18). Resting physiology without hyperemia
achieved an accuracy of w80% compared with FFR,
both retrospectively (80.4% for iFR; 81.5% for Pd/Pa)
(5) and prospectively (82.5% for iFR; 83.2% for Pd/Pa)
(10) from a total of >2,200 lesions. In the current
study, resting physiology similarly achieved an ac-
curacy of w80% (79.9% for iFR; 78.5% for Pd/Pa),
which contrast hyperemia signiﬁcantly improved to
85.8%.
Thus, a pyramid of diagnostic accuracy arises from
thousands of patients in multiple studies: no accu-
racy (50%), angiography (65%), resting physiology
(80%), contrast hyperemia (85%), FFR (95%). Clear
improvements in diagnostic performance can be
achieved by adding angiography, then physiology,
and ﬁnally the hyperemic continuum. As a parallel,
the numeric value of FFR displays a continuous
relationship with clinical outcomes both before and
TABLE 3 Review of Existing Literature on Contrast FFR
Lesions Country Reference Contrast Dose Repeatability Core Lab iFR Cutoff Accuracy, % AUC
763 International This paper 8 different Pragmatic Yes Yes Yes 0.83 85.8 0.930
328 Spain (19) NR 6 ml No No No 0.90 NR 0.92
108 France (20) Iodinaxol or iomperol RCA ¼ 6 ml, LCA ¼ 10 ml No No No 0.85 86 0.94–0.98
104 Italy (21) Iomeprol 6 ml Yes No No 0.83 85 0.98
98 Portugal (22) Iodinaxol or iopromide 10 ml 10% subset No No 0.84 89.9 0.965
80 Japan (23) Iomeprol 6 ml Subset Yes No 0.84 87.5 0.93
37 United States (24) Iodixanol 6 ml No No No NR NR NR
21 Belgium (25) Iohexol 6 ml No No No NR NR NR
AUC ¼ area under the receiver-operating characteristic curve; LCA ¼ left coronary artery; NR ¼ not reported; RCA ¼ right coronary artery; other abbreviations as in Table 2.
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765after revascularization (8). The 2 related continua
thereby link the degree of hyperemia with subse-
quent risk, implying that strong vasodilators yield
optimal and personalized selection for revasculari-
zation. As such, our study provides a fundamental
physiological and mechanistic link between pharma-
cological stress and patient care.
COMPARISON WITH EXISTING LITERATURE. Table 3
compares our results with those of others studies
that have looked at cFFR speciﬁcally (19–25). Notable
features of the current study include its larger sample
size, international patient population, pragmatic
choice of contrast medium and dose, uniform test/
retest repeatability, central and blinded core lab, and
iFR measurement. Nevertheless, our cFFR threshold
and its diagnostic performance broadly agree with
those reported by others.
Several studies have compared resting physiology
with FFR, and our results provide an independent
validation of these existing ﬁndings. Our Pd/Pa ac-
curacy of 78.5% approximates other results (81.5% [5]
and 83.2% [10]), as does the 0.875 area under the ROC
curve (0.880 [26], 0.82 [5], and 0.90 [10]). Similarly,
our iFR accuracy of 79.9% agrees with other results
(80.4% (5) and 82.5% [10]) as does the 0.881 area
under the ROC curve (0.871 [26], 0.81 [5], and 0.90
[10]). In agreement with our results, all previous work
has also found an equivalent accuracy and/or ROC
area between Pd/Pa and iFR (5,10,26) due to their
highly linear relationship (5). Finally, our results
conﬁrm previous reports that the value during the iFR
period decreases from rest to hyperemia and that FFR
has a superior test/retest repeatability (26).
STUDY LIMITATIONS. Contrast medium produces a
shorter period of hyperemia than an IC bolus of
adenosine, as displayed visually in Figure 2 and
quantiﬁed in earlier work (25). Therefore, neither
agent can be used to produce a pull-back tracing todistinguish diffuse from focal disease. However, both
techniques permit rapid serial measurements along
the artery. Alternatively, after observing a low, distal
cFFR value, operators could switch to a longer acting
drug like IV adenosine or regadenoson for a pullback.
In order to make our results generally applicable,
we speciﬁcally designed a pragmatic protocol with
respect to contrast medium and volume. A post hoc
exploration suggested heterogeneity among contrast
media, although our protocol was not designed to
answer this separate question. Our results did not
support a signiﬁcant effect of contrast volume within
the 6 to 10 ml used in almost 98% of cases, but smaller
or larger contrast volumes might produce a different
degree of hyperemia. A paired study using several
contrast media or volumes in random order for the
same lesion could be performed. However, typically
hospitals choose their contrast medium and operators
choose their contrast volume for many reasons
distinct from its coronary hyperemic potential.
Possibly cFFR measured using a speciﬁc contrast
medium and volume could reach an accuracy of
w90% compared with adenosine FFR.
We did not collect data on contrast-induced ne-
phropathy. The average IC contrast dose was 8  2 ml
per measurement, and some operators document
wire position using contrast as part of the clinical
procedure. A validated risk score for contrast-
induced nephropathy assigns 1 point per 100 ml of
contrast volume, such that an extra 10 ml would have
an odds ratio of w1.025 (27). Thus, we believe that
the impact of this small amount of extra contrast
has negligible clinical signiﬁcance for the vast
majority of patients. We did not mandate ﬂushing
catheters after an IC injection (contrast or adeno-
sine), potentially producing dampened aortic curves
that would have been excluded during core lab
review. However, only 10% of tracings were rejected
for any reason, implying at most a small effect in the
entire cohort.
PERSPECTIVES
WHAT IS KNOWN? FFR requires maximal vasodila-
tion, usually achieved with adenosine. Because
radiographic contrast injection causes submaximal
coronary hyperemia, it could provide an easy and
inexpensive tool for predicting FFR.
WHAT IS NEW? cFFR achieves an accuracy of
w85% compared with adenosine-based FFR. It offers
superior diagnostic performance and repeatability
compared with Pd/Pa and iFR.
WHAT IS NEXT? Future studies evaluating
adenosine-free indexes should include cFFR in their
protocols.
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766CLINICAL RELEVANCE AND CONCLUSIONS
Some operators prefer to avoid adenosine when per-
forming physiological lesion assessment due to rare
side effects and minimal but nonzero added time and
expense. Additionally, adenosine remains expensive
or unavailable in some areas of the world, and occa-
sional patients have contraindications. Our results
demonstrate that for these operators, health care
systems, and clinical scenarios, cFFR predicts FFR
better than Pd/Pa or iFR using either a binary or
hybrid approach. Additionally, measuring cFFR is
more repeatable and more linear with respect to FFR.
Further advantages of cFFR include its universal and
immediate availability independent of special soft-
ware or a valid electrocardiogram tracing, unlike iFR.
However, FFR with strong hyperemia like adenosine
remains the reference standard in the pyramid of
diagnostic accuracy.
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